Thanks for the link.
There appears to be nothing about Axiron, but the deal costs get a mention in EPS numbers, then explained at the bottom.
"In addition, the first quarter 2010 financial statements have been adjusted to eliminate a charge of $50.0 million (pretax), or $0.03 per share (after-tax), for acquired in-process research and development associated with the in-licensing agreement with Acrux Ltd.
